Welcome to our dedicated page for Ascendis Pharma A/S SEC filings (Ticker: ASND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ascendis Pharma A/S's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ascendis Pharma A/S's regulatory disclosures and financial reporting.
Artisan Partners Asset Management Inc., together with affiliated entities, reports beneficial ownership of Ascendis Pharma A/S ordinary shares. The group beneficially owns 2,634,024 ordinary shares, representing 4.2% of the class, based on 61,977,408 shares outstanding as of May 11, 2026.
The group has shared voting power over 2,422,862 shares and shared dispositive power over all 2,634,024 shares, with no sole voting or dispositive power. The filing states ownership of 5 percent or less of the class and identifies Artisan Partners Limited Partnership as an investment adviser registered under the Investment Advisers Act of 1940.
Ascendis Pharma A/S reported a strong turnaround for the quarter ended June 30, 2026. Total revenue rose to €339.3 million from €158.0 million a year earlier, driven mainly by commercial products, including YORVIPATH, SKYTROFA and the new product YUVIWEL.
Operating profit reached €220.5 million versus a loss of €53.0 million in 2025, supported by higher product revenue and €158.1 million of other operating income from sale of a priority review voucher (PRV). Net profit improved to €207.0 million, or €2.83 diluted EPS, compared with a net loss of €38.9 million.
Non-IFRS operating profit was €92.0 million, and non-IFRS net profit was €61.3 million, or €0.90 per diluted share. For the first half of 2026, cash flows from operating activities were €274.0 million, and cash and cash equivalents were €812.3 million as of June 30, 2026, with 66,189,926 ordinary shares outstanding.
Ascendis Pharma A/S reported sharply improved results for the six months ended June 30, 2026. Revenue rose to €585.9M from €259.0M a year earlier, driven by commercial products YORVIPATH, SKYTROFA and the U.S. launch of YUVIWEL, plus milestone and license income. Gross profit increased to €540.7M. Operating profit reached €245.3M versus a prior operating loss.
Net profit for the period was €836.3M, compared with a €133.5M loss, largely reflecting recognition of €699.3M in deferred tax assets and €158.1M of other operating income from selling a Rare Pediatric Disease Priority Review Voucher for $187.5M. Cash from operations was €274.0M, lifting cash and equivalents to €812.3M. The company redeemed $575M of 2.25% convertible notes via conversion into 3,635,813 shares, eliminating €719.4M of current liabilities and convertible-related derivatives. Ascendis also executed a $120M share repurchase program (505,418 shares) while maintaining royalty funding liabilities of €301.8M tied to YORVIPATH and SKYTROFA sales.
Ascendis Pharma A/S granted new employee equity incentives through warrants. On August 11, 2026, the board approved an aggregate grant of 15,060 warrants to certain employees under Appendix 1a to the company’s Articles of Association, and amended the Articles to provide for these grants.
Each warrant entitles the holder to subscribe for one ordinary share at an exercise price of US $254.57 per share, equal to the closing price on the grant date. Subject to earlier vesting upon specified exit events, 25% of the warrants will vest on the one-year anniversary of the grant date, and the remaining 75% will vest in 1/36th monthly installments thereafter, in each case subject to continued service. After this grant, warrants to subscribe for an additional 1,524,443 shares remain available for future grant under the Articles of Association.
Ascendis Pharma A/S reports clinical and program updates across its achondroplasia franchise. In the Phase 2 open-label COACH trial, once-weekly combination therapy with TransCon CNP (100 µg/kg/week) and TransCon hGH (0.30 mg/kg/week) in children with achondroplasia continued to show durable growth, with mean annualized growth velocity at or above the 97th percentile of children of average stature at Week 78, while maintaining safety and tolerability.
The COACH trial includes 12 TransCon CNP–naïve children (mean age 5.26 years) and 9 previously treated children (mean age 8.32 years) who had received TransCon CNP monotherapy for a mean of 2.56 years. Across completed and ongoing trials, TransCon CNP monotherapy demonstrated durable height gains, additional benefits beyond height, and a safety profile similar to placebo with low injection site reactions. Ascendis also references U.S. launch progress for YUVIWEL (navepegritide) through June 30, 2026, and outlines forward-looking plans and risks related to regulatory filings, key trials, commercialization, funding, and broader operational uncertainties.
Ascendis Pharma A/S granted 14,060 warrants to certain employees on July 14, 2026 under Appendix 1a to its Articles of Association. Each warrant entitles the holder to subscribe for one ordinary share at an exercise price of US $265.57 per share.
Subject to earlier vesting upon specified exit events and continued service, 25% of the warrants vest on the first anniversary of the grant date and the remaining 75% vest in equal monthly installments over 36 months thereafter. After this grant, warrants to subscribe for 1,539,503 additional shares remain available for future grants. The report is deemed incorporated by reference into the company’s existing Form S-8 and Form F-3 registration statements.
Ascendis Pharma A/S filed a Form 6-K highlighting new Week 104 radiographic data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. Children treated with TransCon CNP showed continued improvements in lower extremity alignment, including tibial-femoral angle, through up to two years of treatment.
The company notes that previously reported gains in annualized growth velocity and ACH-specific height Z-score were maintained through Week 104. TransCon CNP was generally well tolerated, with a low rate of mild injection site reactions, no symptomatic hypotension, no acceleration of bone age, and no adverse events leading to treatment discontinuation or withdrawal.
Ascendis Pharma A/S reports the closing of a warrant exercise window for its outstanding warrants linked to ordinary shares. During this window, holders exercised warrants resulting in registered share capital increases of nominal DKK 177,267.
This raised the company’s total share capital to nominal DKK 66,189,926 through the issuance of 177,267 new ordinary shares. Ascendis received average cash consideration of approximately USD $121.57 per share, based on the DKK-USD exchange rate on June 29, 2026. The company’s articles of association were updated to reflect the new capital and are included as an exhibit.
Ascendis Pharma A/S has completed the sale of its U.S. Rare Pediatric Disease Priority Review Voucher to an undisclosed buyer for $187.5 million in cash before transaction-related expenses. The Priority Review Voucher was granted by the U.S. Food and Drug Administration following approval of YUVIWEL® (navepegritide) in February 2026.
This Form 6-K is also incorporated by reference into Ascendis Pharma’s existing registration statements on Form S-8 and Form F-3, meaning the information becomes part of those shelf and equity compensation registration documents.
Ascendis Pharma A/S filed a report highlighting Week 182 results from its completed Phase 3 PaTHway Trial of TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism. Over three and a half years, TransCon PTH showed sustained efficacy and safety, replicating the actions of natural parathyroid hormone across key organs, including the central nervous system, kidneys, small intestine, and bone.
The trial reported improved quality of life and normalized, stable measures such as urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were maintained while allowing most patients to become independent from conventional therapy using active vitamin D and calcium supplements, based on predefined trial endpoints.